These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18226262)

  • 1. In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.
    Khositnithikul R; Tan-Ariya P; Mungthin M
    Malar J; 2008 Jan; 7():23. PubMed ID: 18226262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa.
    Happi CT; Gbotosho GO; Folarin OA; Milner D; Sarr O; Sowunmi A; Kyle DE; Milhous WK; Wirth DF; Oduola AM
    Malar J; 2006 Oct; 5():82. PubMed ID: 17020611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atovaquone-Proguanil Remains a Potential Stopgap Therapy for Multidrug-Resistant Plasmodium falciparum in Areas along the Thai-Cambodian Border.
    Saunders DL; Chaorattanakawee S; Gosi P; Lanteri C; Somethy S; Kuntawunginn W; Ittiverakul M; Chann S; Gregory C; Chuor CM; Prom S; Spring MD; Lon C
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1896-8. PubMed ID: 26711753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe.
    Wichmann O; Muehlberger N; Jelinek T; Alifrangis M; Peyerl-Hoffmann G; Muhlen M; Grobusch MP; Gascon J; Matteelli A; Laferl H; Bisoffi Z; Ehrhardt S; Cuadros J; Hatz C; Gjorup I; McWhinney P; Beran J; da Cunha S; Schulze M; Kollaritsch H; Kern P; Fry G; Richter J;
    J Infect Dis; 2004 Nov; 190(9):1541-6. PubMed ID: 15478057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.
    Musset L; Pradines B; Parzy D; Durand R; Bigot P; Le Bras J
    J Antimicrob Chemother; 2006 Jan; 57(1):110-5. PubMed ID: 16319183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations.
    Musset L; Bouchaud O; Matheron S; Massias L; Le Bras J
    Microbes Infect; 2006 Sep; 8(11):2599-604. PubMed ID: 16962361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.
    Sutherland CJ; Laundy M; Price N; Burke M; Fivelman QL; Pasvol G; Klein JL; Chiodini PL
    Malar J; 2008 Nov; 7():240. PubMed ID: 19021900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana.
    Muehlen M; Schreiber J; Ehrhardt S; Otchwemah R; Jelinek T; Bienzle U; Mockenhaupt FP
    Trop Med Int Health; 2004 Mar; 9(3):361-3. PubMed ID: 14996365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of cytochrome b mutations in Plasmodium falciparum isolates in Thai-Myanmar border.
    Naoshima-Ishibashi Y; Iwagami M; Kawazu S; Looareesuwan S; Kano S
    Travel Med Infect Dis; 2007 Mar; 5(2):132-4. PubMed ID: 17298921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola.
    Pimentel S; Nogueira F; Benchimol C; Quinhentos V; Bom J; Varandas L; do Rosário V; Bernardino L
    Malar J; 2006 Apr; 5():30. PubMed ID: 16597338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of Cytochrome
    Lin JT; Waltmann A; Moser KA; Park Z; Na YB; Aydemir O; Brazeau NF; Gosi P; Marsh PW; Muller MS; Spring M; Sok S; Bailey JA; Saunders DL; Lon C; Wojnarski M
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.
    Ingasia LA; Akala HM; Imbuga MO; Opot BH; Eyase FL; Johnson JD; Bulimo WD; Kamau E
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1818-21. PubMed ID: 25583715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene.
    Wichmann O; Muehlen M; Gruss H; Mockenhaupt FP; Suttorp N; Jelinek T
    Malar J; 2004 Jun; 3():14. PubMed ID: 15186499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone-proguanil in traveller returning from Congo.
    Massamba L; Madamet M; Benoit N; Chevalier A; Fonta I; Mondain V; Jeandel PY; Amalvict R; Delaunay P; Mosnier J; Marty P; Pomares C; Pradines B
    Malar J; 2020 Jan; 19(1):37. PubMed ID: 31964401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.
    Staines HM; Burrow R; Teo BH; Chis Ster I; Kremsner PG; Krishna S
    J Antimicrob Chemother; 2018 Mar; 73(3):581-595. PubMed ID: 29237012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children.
    Tahar R; Almelli T; Debue C; Foumane Ngane V; Djaman Allico J; Whegang Youdom S; Basco LK
    J Infect Dis; 2014 Dec; 210(12):1962-71. PubMed ID: 24943722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted deep amplicon sequencing of kelch 13 and cytochrome b in Plasmodium falciparum isolates from an endemic African country using the Malaria Resistance Surveillance (MaRS) protocol.
    L'Episcopia M; Kelley J; Patel D; Schmedes S; Ravishankar S; Menegon M; Perrotti E; Nurahmed AM; Talha AA; Nour BY; Lucchi N; Severini C; Talundzic E
    Parasit Vectors; 2020 Mar; 13(1):137. PubMed ID: 32171330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and genotypic characterization of Thai isolates of Plasmodium falciparum after an artemisinin resistance containment project.
    Thita T; Jadsri P; Thamkhantho J; Ruang-Areerate T; Suwandittakul N; Sitthichot N; Mahotorn K; Tan-Ariya P; Mungthin M
    Malar J; 2018 May; 17(1):197. PubMed ID: 29764451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First case of emergence of atovaquone resistance in Plasmodium falciparum during second-line atovaquone-proguanil treatment in South America.
    Legrand E; Demar M; Volney B; Ekala MT; Quinternet M; Bouchier C; Fandeur T; Rogier C; Carme B; Puijalon OM; Esterre P
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2280-1. PubMed ID: 17438062
    [No Abstract]   [Full Text] [Related]  

  • 20. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria.
    Fivelman QL; Butcher GA; Adagu IS; Warhurst DC; Pasvol G
    Malar J; 2002 Feb; 1():1. PubMed ID: 12057021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.